Formulation of Ebastine Fast-Disintegrating Tablet Using Coprocessed Superdisintegrants and Evaluation of Quality Control Parameters

Table 7

Evaluated postcompression parameters of fifteen different trial batches.

Batches	Weight variation (mg±SD)	Friability (%)	Hardness (kg/cm^2 ± SD)	Thickness (mm ± SD)	Drug content (% ± SD)	Dissolution (%)
B1	200.05 ± 1.98	0.443	4.5 ± 0.57	3.04 ± 0.01	99.51 ± 2.49	89.83 ± 2.44
B2	199.71 ± 1.77	0.398	3.2 ± 0.27	3.01 ± 0.02	99.01 ± 2.10	95.61 ± 2.1
B3	199.81 ± 2.24	0.209	3.8 ± 0.44	3.02 ± 0.01	96.92 ± 0.93	94.34 ± 1.97
B4	198.07 ± 2.12	0.877	3.6 ± 0.41	2.99 ± 0.08	101.82 ± 0.83	84.66 ± 0.95
B5	200.09 ± 2.01	0.318	4.4 ± 0.41	3.36 ± 0.03	103.71 ± 0.59	94.55 ± 1.66
B6	200.85 ± 2.05	0.617	3.9 ± 0.65	3.15 ± 0.07	99.24 ± 2.45	94.67 ± 1.82
B7	202.06 ± 2.68	0.274	4.2 ± 0.27	3.04 ± 0.04	94.80 ± 0.93	94.09 ± 1.7
B8	202.5 ± 1.40	0.443	4.3 ± 0.27	3.16 ± 0.18	101.67 ± 2.10	95.78 ± 0.61
B9	202.46 ± 4.31	0.295	3.7 ± 0.75	3.25 ± 0.27	101.86 ± 1.48	94.63 ± 0.62
B10	202.77 ± 2.15	0.219	3.8 ± 0.57	3.27 ± 0.38	102.63 ± 0.72	95.65 ± 2.87
B11	201.47 ± 2.82	0.362	3.9 ± 0.41	3.15 ± 0.18	96.23 ± 2.27	96.27 ± 2.10
B12	202.14 ± 2.53	0.361	3.66 ± 0.11	3.15 ± 0.11	103.48 ± 1.16	94.98 ± 3.00
B13	198.36 ± 2.63	0.310	4.42 ± .23	3.15 ± 0.23	98.00 ± 0.04	86.58 ± 1.56
B14	203.79 ± 2.32	0.368	3.68 ± 0.13	3.34 ± 0.19	97.54 ± 1.33	95.17 ± 2.44
B15	202.52 ± 2.44	0.466	3.8 ± 0.15	3.15 ± 0.17	101.01 ± 0.20	87.70 ± 2.79